Ready to reconnect?

People with PI who infuse CUVITRU^® [Immune Globulin Subcutaneous (Human)] 20% Solution weekly or every other week may be able to experience more of these moments.

Infusions tailored to you.^1*†

Fewer needlesticks

In the study, most (84.9%) used 1 to 2 needlesticks.

Flexible schedule

CUVITRU gives you and your doctor the freedom to tailor your PI treatment to your lifestyle with weekly or every-other-week infusions.

Faster infusions

CUVITRU can be infused at the fastest rates and highest volumes with the fewest infusion sites of any subQ IG.^‡

^*CUVITRU was studied in 77 people with primary immunodeficiency (PI) ≥2 years of age. The average infusion time was 0.95 hours (range, 0.2-6.4 hours).

^†You’ll infuse your first 2 infusions at 10 to 20 mL/hour/site. After that, you’ll be able to increase your rate, as tolerated.

^‡CUVITRU can be infused at the fastest rates of any subQ (up to 60 mL/hour/site as tolerated). You’ll infuse your first 2 infusions at 10 to 20 mL/hour/site. After that, you'll be able to increase your rate to 60 mL/hr/site, as tolerated. Infuse at up to 4 sites simultaneously.

CUVITRU gives you flexible options. Work with your doctor to pick the right way to infuse for you.

Together, you can choose:

How many infusion sites
How much CUVITRU to infuse at each site
How fast to infuse it
How often to infuse

Learn more about infusions

Considering CUVITRU?

Watch a video about CUVITRU to help you feel confident about talking with your doctor.

Or download the Consideration Brochure.

CUVITRU is a subQ infusion, not an IVIG infusion.

CUVITRU is given through a subQ, or subcutaneous, infusion, which means it’s given under the skin, unlike other therapies for PI that are given by an intravenous, or IV, infusion, which goes into a vein.

And patients living with PI preferred the convenience of CUVITRU to IVIG infusion.¹

In the North American study, 68 patients (out of 77) were included in an analysis that showed significant improvement vs IVIG in terms of convenience (TSQM-9) and treatment interference (LQI).^1,2*

Patients reported convenience as²:

Ease of using the medication in its current form
Ease of planning when to use the medication each time
Convenience in taking the medication as instructed

They reported treatment interference as²:

Interference with social/family life
Time waiting
Treatment is worthwhile
Dependence on others
Freedom to take trips or move
Scheduled according to patient’s convenience

Quality of life was measured in other areas and did not show a significant improvement for patients: TSQM-9, no significant improvement in how satisfied patients were with their treatment or how effective they felt it was; LQI, no significant change reported in problems related to therapy or the therapy setting. In other assessments, health-related quality of life differences between IVIG and subQ IG treatment were not statistically significant.

IVIG=intravenous immunoglobulin; LQI=Life Quality Index; TSQM=Treatment Satisfaction Questionnaire for Medication.

^*These results came from the LQI and TSQM-9. Both TSQM-9 and LQI were measured in patients aged 2 to 12 (with a parent observer) and in patients aged ≥13 (with the patient as the observer). TSQM-9, P<0.001; LQI, P=0.008.

Not sure what your infusion preferences are?

Fill out the Doctor Discussion Guide to get more familiar with the infusion experience and help guide the conversation with your doctor.

Get the Doctor Discussion Guide

Sometimes it helps to see how others manage their infusion schedules to fit their life.

See patient stories

Side effects are a potential part of any treatment.

CUVITRU has been shown to have a low rate of infusion site side effects at any infusion rate.^*†

There are 2 types of side effects: infusion site side effects (local) and general side effects (systemic).

The most common infusion site side effects reported in ≥5% of patients were pain (20.3%), redness (10.8%), and itching (5.4%).^‡

The most commonly experienced general side effects reported in ≥5% of patients are headache (13.5%), nausea (12.2%), fatigue (8.1%), diarrhea (6.8%), and vomiting (5.4%).

See tolerability study

CUVITRU demonstrated ~7 times fewer systemic side effects common to IVIg^*†1

^*You’ll infuse your first 2 infusions at 10 to 20 mL/hour/site. After that, you'll be able to increase your rate to 60 mL/hr/site, as tolerated.

^†CUVITRU was studied in 77 people with primary immunodeficiency (PI) ≥2 years of age. The average infusion time was 0.95 hours (range, 0.2-6.4 hours).

^‡Infusion site side effects generally go away within a few hours and are less likely after the first few infusions.

^§Systemic side effects affect your whole body (excluding infections) and can occur within 72 hours of your infusion. Systemic side effect rate for fatigue (per infusion): 0.015 [IVIG] and 0.002 [CUVITRU].

Keep scrolling for additional Important Safety Information

References

1. CUVITRU. Prescribing Information, Takeda Pharmaceuticals USA Inc.; 2023.

2. Meckley LM, Wu Y, Ito D, et al. Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary Immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials. BMC Immunol. 2020;21(1):24. doi:10.1186/s12865-020-00346-z

Contact a Rep

IMPORTANT SAFETY INFORMATION and serious warnings regarding blood clots

What is CUVITRU?

CUVITRU is a ready-to-use liquid medicine that is given under the skin (subcutaneously) to treat primary immunodeficiency (PI) in people 2 years and older.

IMPORTANT SAFETY INFORMATION

What is the most important information that I should know about CUVITRU?

CUVITRU can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs, or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.

What is the most important information I need to know about CUVITRU?

CUVITRU can cause the following serious reactions:

Severe allergic reactions causing difficulty in breathing or skin rashes
Decreased kidney function or kidney failure
Blood clots in the heart, brain, lungs, or elsewhere in the body
Severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting
Dark colored urine, swelling, fatigue, or difficulty breathing

Who should not use CUVITRU?

Do not use CUVITRU if you:

Have had a severe allergic reaction to immune globulin or other blood products.
Have a condition called selective (or severe) immunoglobulin A (IgA) deficiency.

What should I avoid while taking CUVITRU?

CUVITRU can make vaccines (like measles/mumps/rubella or chickenpox vaccines) not work as well for you. Before you get any vaccines, tell your healthcare provider (HCP) that you take CUVITRU.
Tell your HCP if you are pregnant, or plan to become pregnant, or if you are nursing.

What are the possible or reasonably likely side effects of CUVITRU?

CUVITRU can cause serious side effects. If any of the following problems occur after starting CUVITRU, stop the infusion immediately and contact your HCP or call emergency services:

Hives, swelling in the mouth or throat, itching, trouble breathing, wheezing, fainting or dizziness. These could be signs of a serious allergic reaction.
Bad headache with nausea, vomiting, stiff neck, fever, and sensitivity to light. These could be signs of irritation and swelling of the lining around your brain.
Reduced urination, sudden weight gain, or swelling in your legs. These could be signs of a kidney problem.
Pain, swelling, warmth, redness, or a lump in your legs or arms. These could be signs of a blood clot.
Brown or red urine, fast heart rate, yellow skin or eyes. These could be signs of a liver or blood problem.
Chest pain or trouble breathing, or blue lips or extremities. These could be signs of a serious heart or lung problem.
Fever over 100°F. This could be sign of an infection.

The following one or more possible side effects may occur at the site of infusion. These generally go away within a few hours, and are less likely after the first few infusions.

Mild or moderate pain
Redness
Itching

The most common side effects that may occur are:

Headache
Nausea
Fatigue
Diarrhea
Vomiting

These are not all the possible side effects. Talk to your HCP about any side effect that bothers you or that does not go away.

For additional safety information, including Warning about Blood Clots, click for Information For Patients and discuss with your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.